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Antipsychotic Drugs on Maternal Behavior in Rats
Ming Li*
Department of Psychology, University of Nebraska-Lincoln, Lincoln, Nebraska, USA
Abstract
Rat maternal behavior is a complex social behavior. Many clinically used antipsychotic drugs, 
including the typical drug haloperidol and atypical drugs clozapine, risperidone, olanzapine, 
quetiapine, aripiprazole and amisulpride, all disrupt active maternal responses (e.g. pup retrieval, 
pup licking and nest building) to various extents. In this review, I present a summary of recent 
studies on the behavioral effects and neurobiological mechanisms of antipsychotic action on 
maternal behavior in rats. I argue that antipsychotic drugs at the clinical relevant doses disrupt 
active maternal responses primarily by suppressing maternal motivation. Atypical drug-induced 
sedation also contributes to their disruptive effects, especially that on pup nursing. Among many 
potential receptor mechanisms, dopamine D2 receptors and serotonin 5-HT2A/2C receptors are 
shown to be critically involved in the mediation of the maternal disruptive effects of antipsychotic 
drugs, with D2 receptors contributing more to typical antipsychotic-induced disruptions, while 5-
HT2A/2C receptors contributing more to atypical drug-induced disruption. The nucleus accumbens 
shell-related reward circuitry is an essential neural network in the mediation of the behavioral 
effects of antipsychotic drugs on maternal behavior. This research not only helps to understand the 
extent and mechanisms of impacts of antipsychotic medications on human maternal care, but also 
is important for enhancing our understanding of the neurochemical basis of maternal behavior. It 
is also valuable for understanding the complete spectrum of therapeutic and side-effects of 
antipsychotic treatment. This knowledge may facilitate the development of effective intervening 
strategies to help patients coping with such undesirable effects.
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Introduction
Maternal behavior in rats is a highly motivated and well-organized social behavior. It is 
naturally expressed for the first time with the birth of the first litter. Within hours of 
parturition, the mother rat reconstructs the nest, retrieves the displaced pups, gathers them 
together in the nest site and adopts a nursing posture over the pups to permit suckling 
(Rosenblatt and Lehrman, 1963; Dollinger et al., 1980). The mother rat (dam) continues to 
exhibit the full repertoire of maternal behavior (pup-licking, pup retrieval, nest-building and 
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nursing) over the subsequent 2–3 week period, although as the pups mature, the intensity 
and quality of her behavior changes (Rosenblatt and Lehrman, 1963; Galef, 1981). Each 
component of maternal behavior, although distinct in appearance and motoric requirements, 
is synchronized seamlessly to ensure the well-being of the young. Psychologically, the dams 
are shown to be less anxious, more attentive to pups or pup-related cues, highly motivated to 
retrieve and protect pups and possessing altered learning and memory ability (Lee et al., 
2000; Lonstein, 2007; Kinsley and Lambert, 2008). Thus the successful expression and 
maintenance of maternal behavior require multiple psychological processes working 
together synergistically.
Maternal behavior is an ecologically valid and complex behavior system that cuts across 
mammalian species and shares many direct features with human mothering behaviors 
(Fleming and Corter, 1988; Rosenblatt, 1989). It is thus a useful model for the study of 
complex behavioral effects and neurobiological mechanisms of psychoactive drugs in a 
social domain. Investigation of the antipsychotic treatment effects on maternal behavior in 
rats represents this aspect of neuropsychopharmacological research.
Antipsychotic drugs (APDs) represent a class of psychoactive drugs that are used to treat 
schizophrenia and other neuropsychiatric disorders (e.g. autism, bipolar disorder, Tourette’s 
syndrome, etc.). Currently they are classified into two groups, typical (or first generation) 
and atypical (or second generation) based on their impacts on prolactin and extrapyramidal 
motor syndromes (EPS) (Kapur and Seeman, 2001), with atypical drugs offering reduced 
risk of EPS and prolactin elevation. Some studies suggest that atypical APDs show superior 
efficacy in improving negative symptoms of schizophrenia (e.g., apathy, lack of motivation, 
and lack of interpersonal and social drive/interaction) (Marder and Meibach, 1994) and 
cognitive impairments (Purdon et al., 2000). However, overall the evidence of this 
superiority has been neither consistent nor robust (Leucht et al., 1999; Lieberman et al., 
2005). It is safe to say that all APDs share a common feature in improving the psychotic 
symptoms of schizophrenia and preventing their recurrence.
In this review, I will present a summary of recent studies from our laboratory on the 
behavioral effects and neurobiological mechanisms of antipsychotic action on maternal 
behavior in rats. Research in this field generally has three purposes in mind. From a 
behavioral neuroscience perspective, studying the effects of antipsychotic treatment on 
rodent maternal behavior will enhance our understanding of the neurochemical basis of 
maternal behavior and the altered psychological processes. Antipsychotic drugs are chemical 
compounds that target dopamine, serotonin and other neurotransmitter systems, notably 
dopamine D2, serotonin 5-HT2A, and/or 5-HT1A receptors. Thus, antipsychotic drugs can be 
used as pharmacological tools to identify the neuroreceptor mechanisms underlying 
maternal behavior. For example, previous research has shown that dopamine D2 receptor is 
important for maternal motivation (Wegener et al., 1988; Giordano et al., 1990; Stern and 
Taylor, 1991; Silva et al., 2001), while the serotonin 5-HT2A and 5-HT2C receptors are 
required for the normal expression of maternal performance (Chen et al., 2014). From a 
psychopharmacology perspective, understanding the effects of antipsychotic action on 
maternal behavior is valuable for the understanding of the complete spectrum of therapeutic 
and side-effects of antipsychotic treatment. Many commonly used animal tests of 
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antipsychotic drugs, such as conditioned avoidance responses, prepulse inhibition of 
acoustic startle or latent inhibition, are simple and have a high predictive validity, yet, they 
are ethologically artificial mechanistic behaviors and may not reflect well the complex and 
multi-dimensional actions of APDs on affective, cognitive and social functions. Thus, the 
study of antipsychotic effects on maternal behavior, a complex and natural social behavior, 
with its onset and expression clearly supported by the coordination and interaction among 
multiple psychological functions (e.g. sensorimotor ability, emotion regulation and 
motivation) would deepen and broaden our understanding of behavioral effects of 
antipsychotic drugs. From a clinical pharmacology perspective, studying the behavioral 
effects of APDs on maternal behavior may have a direct and immediate implication, since 
more than half of the women with schizophrenia in the United States are also mothers 
(Seeman, 2004). Studies on the mother-child relationship reveal that the quality of maternal 
care from mothers with schizophrenia is generally inferior to that from healthy mothers. One 
contributing factor recognized by both patients and their clinicians is antipsychotic 
medications. However, it is not clear to what extent antipsychotic drugs impact the quality 
of maternal care and through what psychological and neurobiological mechanisms. With the 
new generation of APDs, which do not produce sustained hyperprolactinemia, there has 
been an increasing trend of schizophrenic women becoming first-time mothers. 
Understanding the antipsychotic effects on maternal behavior in mother rats, especially in 
those animal models of postpartum schizophrenia, would help us understand the extent and 
mechanisms of impacts of antipsychotic medications on human maternal care. This 
knowledge may facilitate the development of effective behavioral or other intervening 
strategies to help patients coping with such undesirable effects. Given that the quality of 
maternal care has long-lasting cognitive, emotional, behavioral, and social consequences for 
child development, and mothers with schizophrenia have to rely on medications chronically, 
it is clinically significant to know definitively and precisely the impact of antipsychotic 
drugs on the quality of maternal care.
In this review, I will first describe the basic behavioral effects of antipsychotic treatment on 
maternal behavior in rats, then present studies aimed at revealing the neuroreceptor 
mechanisms and neuroanatomical basis of antipsychotic action in maternal behavior. 
Finally, I will discuss the clinical implications of such preclinical studies for the 
understanding of the quality of human maternal care in patients who are also treated with 
antipsychotic medications.
Basic behavioral effects of antipsychotic drugs on maternal behavior in 
rats
Studies in the early 90s aimed at elucidating the role of the dopamine system in maternal 
behavior showed that acutely administered typical antipsychotics, such as haloperidol and 
pimozide, disrupt pup retrieval, pup licking and nest building but not nursing, in postpartum 
female rats. For example, Giordano et al. (1990) found that haloperidol dose-dependently 
inhibited pup retrieval and nest building, but not nursing and pup licking. Hansen et al. 
(1991) showed that raclopride administered to postpartum female mothers also significantly 
inhibited pup retrieval but not nursing. A similar effect of haloperidol on pup retrieval was 
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reported by Stern and Taylor (1991). Animals under the influence of antipsychotics are 
slower to approach pups and retrieve fewer pups. They also spend less time licking their 
offspring and building the nest. Regarding the atypical antipsychotic drugs, Silva et al 
(2001) found that clozapine at an even lower dose (1.5 mg/kg) impaired nest building, but 
not pup retrieval.
In recent years, we conducted a series of experiments that extended these findings to several 
commonly used atypical drugs. We showed that clozapine, risperidone and quetiapine also 
disrupt active components of maternal behavior in a dose-dependent fashion (Li et al., 
2004). Our results indicate that clinically comparable doses of haloperidol, clozapine, 
risperidone, and quetiapine (based on the 50–80% striatal D2 receptor occupancy and 
efficacy in disrupting the conditioned avoidance response) (Wadenberg et al., 2000) show 
no qualitative or quantitative differences in their disruptions but display different temporal 
characteristics. Haloperidol causes a prolonged disruption (up to 6 h after injection), 
whereas clozapine, risperidone, and quetiapine induce an early onset but transient disruption 
(~2 h). We attributed this temporal difference to the distinct temporal binding profiles of the 
D2 receptor binding between haloperidol and the other drugs (haloperidol having a tighter 
binding to the D2 receptor and dissociating from it at a slower rate than atypical drugs), 
rather than some other fundamental differences (Meltzer et al., 1989; Kapur and Seeman, 
2000, 2001; Seeman, 2000). It has been shown that after an acute administration (in non-
pregnant animals) haloperidol shows prolonged D2-related therapeutic effects and side-
effects, whereas the effects of clozapine/risperidone/quetiapine tend to be more transient 
(Kapur and Seeman, 2001). Additionally, we found that other atypical antipsychotics such as 
olanzapine, amisulpride and aripiprazole also exhibit a certain degree of inhibition of active 
maternal responses in a dose-dependent fashion (Li et al., 2005b; Zhao and Li, 2012). 
Chronic treatment with haloperidol or olanzapine (another widely prescribed atypical 
antipsychotic drug) via mini-pumps or repeated daily injections also significantly inhibits rat 
active maternal responses (Li et al., 2005a). It seems that the antipsychotic-induced 
inhibition of pup retrieval, pup licking, and nest building may be an inherent feature of all 
currently available antipsychotics.
In contrast to the consistent suppressive effects of these APDs on active maternal behavior, 
their effects on nursing behavior diverged. Haloperidol had no effects on nursing. This is 
consistent with previous studies that also show that haloperidol does not disrupt nursing 
behavior (Giordano et al., 1990) and may even increase nursing duration (Stern and Taylor, 
1991). However, clozapine, risperidone, olanzapine and quetiapine all showed an inhibitory 
effect on nursing behavior at some points during the tests.
So far, all work has been focused on the direct effect of antipsychotic treatment on the 
behaviors of mothers. In a recent study we examined the effect of antipsychotic treatment to 
mother rats on their offspring’s ultrasonic vocalizations (USV) as an indirect way of 
assessing the impact of antipsychotic treatment on the quality of maternal care (Li et al., 
2011). Rat pups often emit USV centered around 40 kHz as a response to various stressors 
(e.g. isolation, shock, temperature change, etc.), and as an early communicative behavior 
between pup and mother (Shair, 2007). An isolated pup would increase its emission of USV 
when it is briefly reunited with its mother and separated again. This potentiated effect is 
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termed “maternal potentiation” of pup USV and is believed to reflect a filial bond that has 
been formed by the pup during the first weeks of life (Shair, 2007). We took advantage of 
the facts that rat pups often increase emission of USV in response to separation and re-
separation from dams, and that the potentiation of pup USV after a brief contact with dams 
presumably reflects different maternal experience (Shair, 2007). Therefore, changes in pup 
USV may reveal the subtle negative impact of antipsychotic treatment on maternal behavior 
of mother rats. We hypothesized that pups of antipsychotic-treated mother rats would show 
an increase in USVs as a compensatory response to their lack of adequate maternal care. On 
postnatal days 10, 12 and 14, mother rats were injected subcutaneously with either 
clozapine, haloperidol or sterile water. Then pups were taken away from their dams and 
placed in individually in separate bowls and tested for USV for 3 minutes (the 1st test). After 
the 1st test, half of the littermates were returned to the dam for 4.5 minutes (termed 
“maternal”), whereas another half were returned to the bowls with a heating pad underneath 
(termed “control”). At the end of the 4.5 minutes, the pups were tested again for USV for 3 
minutes (the 2nd test), after which, all pups were returned to their mothers. We found that 
initial maternal separation (1st test) induced pup USVs and re-separation (2nd test in the 
“maternal” condition) further enhanced the number of pup USVs, confirming the maternal 
potentiation effect). Clozapine increased pup USVs in pups that were briefly reunited with 
their dams between the two tests, while it had little effect in pups that were not reunited with 
their dams. This finding suggests that altered maternal behavior exhibited by clozapine-
treated dams during the 4.5-minute reunion period contributed to an increase in the number 
of pup USVs. In contrast to the effect of clozapine, haloperidol did not seem to have a great 
impact on pup USV. Because clozapine differs from haloperidol on pup nursing (i.e. 
haloperidol increases pup nursing, whereas clozapine decreases it), we speculated that the 
most likely cause of the potentiating effect of clozapine on pup USV is its disruptive effect 
on pup nursing. Clozapine also antagonizes histamine H1 receptors and/or adrenergic 
receptors and causes a severe sedation (Fleischhacker et al., 1994), so the observed effect of 
clozapine on pup USVs could be attributed to drug-induced sedation and sedation-induced 
alteration of maternal behavior via actions on H1 receptors and/or adrenergic receptors (see 
below for a further study on this issue). Thus, this pup USV study introduced an innovative 
approach to study the behavioral effects of antipsychotic medication on rat maternal 
behavior. This paradigm may also be valuable for examining the effects of other 
psychoactive drugs on the developmental trajectory of the young and allows us to 
investigate the neurobiological processes underlying the mother-infant interactions.
Behavioral mechanisms: motoric, motivational, or sedative effects?
Although the antipsychotic-induced disruption of rat active maternal behavior is clear and 
robust, its underlying behavioral mechanisms are not. Since maternal behavior has 
motivational as well as motor components, and given that antipsychotic drugs (at least the 
typical ones) are known to produce motivational and motoric impairments (Ikemoto and 
Panksepp, 1999; Salamone and Correa, 2002), it raises the question of whether this 
disruptive effect is motivational or simply motoric. In addition, because atypical drugs like 
clozapine also give rise to sedation due to their actions on histamine H1 receptors and/or 
adrenergic receptors (Fleischhacker et al., 1994), the atypical drug-induced disruption also 
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could be attributed to drug-induced sedation. Several findings suggest that the maternal 
disruptive effect of antipsychotic treatment is not just a motor deficit: First, postpartum 
mothers treated with even 0.2 mg/kg haloperidol are able to pick up food pellets and carry 
them back to the nest (Giordano et al., 1990), suggesting that pup retrieval and nest building 
deficits are observed in the presence of other preserved motor and oral-manipulation 
behaviors (Giordano et al., 1990). Second, in our hands and those of others, haloperidol at 
0.1 mg/kg does not produce catalepsy (De Ryck et al., 1982; Wadenberg et al., 2000), but it 
did produce maternal deficits, suggesting that this measure is not merely another 
manifestation of catalepsy. Third, atypicals such as clozapine, risperidone and quetiapine are 
well known for their lack of effect on catalepsy, especially at the doses employed in our 
study (Kapur et al., 2003). Fourth, Giordano, et al, (1990) and tour study both found that 0.2 
mg/kg haloperidol impairs pup retrieval when there is little or no mother-pup separation 
before testing. However, when 0.2 mg/kg haloperidol treated rats are pup-deprived for 4 h 
before observation, they show quite normal pup retrieval (Stern & Taylor, 1991).
To directly address the motivational versus motoric issue, we employed a pup-separation 
technique (Zhao and Li, 2009c). Previous work shows that removing pups from dams for 
several hours (>3 h) prior to maternal tests can significantly increase a mother rat’s maternal 
motivation and stimulate dopamine release in the ventral striatum of maternal rats (Hansen 
et al., 1993; Hansen, 1994). Three to six hours of pup deprivation can completely restore the 
pup retrieval deficit induced by massive dopamine depletion (80%) in the ventral striatum 
region in postpartum female rats (Hansen, 1994). Therefore, we reasoned that if the 
antipsychotic-induced maternal behavior deficits are primarily motivational, we would 
expect to see that antipsychotic-treated rats under this manipulation show improved maternal 
performance compared to testing under the standard condition (no-pup separation). No such 
improvement was expected to be observed if the deficits are motoric. We showed that 
separation of the pups from their mothers for 4h before testing significantly shortened pup 
approach latency, enhanced pup licking activity, and stimulated nursing behavior. Since pup 
separation is shown to affect maternal motivation, this observation suggests that 
antipsychotic-induced maternal deficits are motivational. This notion is also consistent with 
other evidence showing that disruptions of the mesolimbic dopamine system generally cause 
a deficit in maternal motivation, but not maternal performance (Hansen et al., 1991; Fleming 
et al., 1994a; Hansen, 1994; Keer and Stern, 1999; Stern and Keer, 1999). For example, 
Stern and Keer (1999) observed that when a dam is fitted with a muzzle, she persistently 
attempts to make snout contact with pups by pushing them with the muzzle. Using the 
muzzle-pushing and handling as indices of maternal motivation, they found that 0.05 mg/kg 
of haloperidol, a dose too low to affect actual pup retrieval under their testing conditions, 
significantly reduced muzzle-pushing and actual contact with pups, although the latency to 
initiate these behaviors was not impaired, indicating that dopamine deficits specifically 
impaired motivation. Pereira and Ferreira (2006) also reported that haloperidol-induced 
maternal behavior deficits can be overcome by testing mother rats with 12 h-isolated pups 
(demanding pups), which presumably are more effective in activating mothers’ maternal 
motivation to retrieve and lick pups (Pereira and Ferreira, 2006).
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Recently, we investigated the validity of a novel pup-based repeated elevated plus maze task 
to detect maternal motivation and explored the motivational aspect of haloperidol treatment. 
Sprague-Dawley postpartum or nulliparous female rats were tested 4 times every other day 
on postpartum days 4, 6 and 8 in an elevated plus maze with 4 pups placed on each end of 
the two open arms. Each test lasted 10 min and each rat was tested at baseline, 30 min, 100 
min or 240 min after an injection of sterile water (vehicle) or haloperidol. Under the vehicle 
condition, postpartum rats retrieved pups into the closed arms, entered the open arms and 
closed arms more and had a higher moving speed than nulliparous rats. Thus, besides the 
number of pup retrieval and number of arm entries, the moving speed appeared to be another 
sensitive measure of maternal motivation. Haloperidol treatment not only dose- and time-
dependently decreased the number of pup retrieval, but also decreased the moving speed. 
This finding provides another indirect evidence suggesting that antipsychotic drugs such as 
haloperidol disrupt maternal behavior via the action on maternal motivation. This idea and 
above findings are also consistent with the motivational salience hypothesis of antipsychotic 
action espoused by Kapur’s group (Kapur, 2003; Kapur et al., 2005, 2006), which suggests 
that antipsychotic drugs have a general effect of suppressing incentive salience of stimuli (in 
this case, pups and pup-related cues).
To examine the extent to which antipsychotic drug-induced sedation contributes to the 
disruption of active maternal behavior, we employed a repeated-treatment schedule and 
compared the effect of antipsychotics with that of chlordiazepoxide, an anxiolytic drug with 
a sedative effect (File, 1984). It is well known that with repeated drug administration, the 
sedative effect of antipsychotics and anxiolytics is greatly diminished (Chesler and 
Salamone, 1996), and tolerance can be seen with only four injections (File, 1984; Sanger, 
1985). In the meantime, antipsychotic efficacy is progressively enhanced with repeated drug 
administration (Agid et al., 2003; Li et al., 2007). If drug-induced sedation plays a role in 
disrupting active maternal behavior, we expected that the haloperidol- and clozapine-
induced maternal behavior deficits will show an improvement with repeated drug treatment. 
If this disruptive effect mainly reflects the motivational effect (Li et al., 2004), the 
haloperidol- and clozapine-induced deficits would persist and show a deterioration with 
repeated drug treatment. Our results show that repeated haloperidol treatment produces a 
progressively enhanced disruption of pup retrieval and nest building and an attenuated 
sedation. In contrast, clozapine shows a progressively diminished disruption of pup retrieval 
and a concomitantly diminished sedative effect. Based on these findings, we suggest that 
acute haloperidol and clozapine disrupt active maternal responses primarily by suppressing 
maternal motivation, and drug-induced sedation also contributes to this disruptive effect, 
especially with clozapine.
Neurochemical mechanisms: dopamine D2 receptors and/or 5-HT2A/2C?
For typical antipsychotics, it is generally assumed that they disrupt maternal behavior by 
blocking dopamine D2 receptors because they are primarily dopamine D2 antagonists 
(Seeman et al., 1976; Dragunow et al., 1990), and because apomorphine, a dopamine 
receptor agonist, can reverse the inhibitory effects of haloperidol (Giordano et al., 1990). 
Because atypical antipsychotics (e.g., clozapine, olanzapine) generally have multiple-
receptor binding profiles (Meltzer et al., 1989; Miyamoto et al., 2005), it is hard to pinpoint 
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their exact neurochemical mechanisms. Most atypicals possess a much more potent 
antagonism on the 5-HT2A receptor in addition to relatively weak antagonism on D2 
receptors (Meltzer et al., 2003). It is thus possible that the disruptive effect of atypical drugs 
on maternal behavior could be attributed to their action on D2 receptors alone (Kapur and 
Seeman, 2001) or to their dual actions on both 5-HT2A and D2 receptors (Meltzer et al., 
1989) or on other receptors such as D1, H1 and adrenergic receptors. Regarding the 5-HT2A 
receptor, the main target of atypical antipsychotic drugs, limited evidence suggests that it is 
involved in maternal aggression, as DOI (2,5-dimethoxy-4-iodo-amphetamine, a preferential 
5-HT2A agonist) and quipazine (a 5-HT2A receptor antagonist) both decreased maternal 
aggressive behavior (Olivier et al., 1995). In our examination of the neurochemical 
mechanisms that mediate the disruptive effect of haloperidol and clozapine (Zhao and Li, 
2009b), we treated postpartum rats with haloperidol or clozapine together with either vehicle 
(saline or water), quinpirole or DOI. Maternal behaviors were tested at different time points 
before and after drug administration. We examined which of these two agonists was able to 
reverse the disruptive effects induced by haloperidol and clozapine. We found that both 
doses of quinpirole significantly improved the haloperidol-induced deficits in pup retrieval, 
pup licking, and nest building. Haloperidol-treated rats pretreated with quinpirole showed 
more shortened pup approach and retrieval latency than those pretreated with vehicle, and 
they retrieved more pups than the vehicle controls. By contrast, DOI failed to improve the 
haloperidol-induced disruption of maternal behavior, suggesting that haloperidolacts through 
its blockade of D2/3 receptors.
In contrast to its effects on haloperidol-induced maternal behavior deficits, quinpirole had 
little effect on the clozapine-induced disruption. It even exacerbated the clozapine-induced 
disruption of pup retrieval and nest building. Interestingly, pretreatment of DOI dose-
dependently improved the clozapine-induced disruption of pup approach, pup retrieval, and 
pup licking, but not nest building and pup nursing. Therefore, for the first time, this study 
demonstrates an interesting double dissociation between dopamine and serotonin receptor 
mechanisms in the mediation of haloperidol (a typical antipsychotic)- and clozapine (an 
atypical antipsychotic)-induced maternal behavior deficits in postpartum rats. These data 
strongly suggest that the haloperidol-induced maternal deficits are primarily mediated by the 
blockade of D2/3 dopamine receptors, whereas the clozapine-induced maternal deficits are 
primarily mediated by the blockade of 5-HT2A/2C receptors.
Given the known antagonistic interaction between dopamine D2 and adenosine A2A 
receptors in the nucleus accumbens (Chen et al., 2001), Pereira (2011) hypothesized that 
antagonizing adenosine A2A receptor would enhance D2-mediated neurotransmission, which 
in turn, would reduce haloperidol-induced maternal disruption. They administered a 
selective adenosine A2A receptor antagonist MSX-3 together with haloperidol to postpartum 
female rats and found that MSX-3 (0.25–2.0 mg/kg, I.p.) produced a dose-related 
attenuation of the haloperidol-induced behavioral deficits on pup retrieval, pup licking and 
nest building. The intermediate doses of MSX-3 (0.5 and 1.0 mg/kg) also reversed the 
increase in nursing behaviors induced by haloperidol. This finding is in support of the idea 
that haloperidol disrupts maternal behavior primarily through its action on dopamine D2 
receptor. It should be noted that because APDs all have unique receptor binding profiles and 
Li Page 8
Behav Pharmacol. Author manuscript; available in PMC 2016 September 01.
Author M
anuscript
Author M
anuscript
Author M
anuscript
Author M
anuscript
act on multiple receptors (Miyamoto et al., 2005), they could affect maternal behavior via 
other neurochemical mechanisms, such as D1, D3, D4, 5-HT1A, 5-HT2C, 5-HT6 or 5-HT7, 
α1, α2, m1, H1, etc. Besides the neuroreceptors, antipsychotic drugs may also influence 
maternal behavior by affecting other biological processes, including actions on neurotrophic 
factor levels, neurogenesis, neuronal plasticity, mitochondrial biogenesis, cell energetics, 
and antioxidant defense enzymes (Lieberman et al., 2008). At present, a complete picture of 
the neurochemical basis of antipsychotic effects on maternal behavior is still lacking.
Neuroanatomical basis of antipsychotic treatment effect on maternal behavior
The ability of antipsychotics to induce c-Fos expression (a protein product of immediate-
early gene c-fos) in forebrain regions has become a widely used molecular tool for 
identifying drugs with potential antipsychotic activity and liability for producing 
extrapyramidal side effects (EPS) (Robertson and Fibiger, 1992; Robertson et al., 1994; Mo 
et al., 2005; Natesan et al., 2006). For example, haloperidol and clozapine are shown to 
produce different induction patterns of c-Fos expression in the forebrain, with haloperidol 
increasing Fos-positive neurons in the dorsolateral striatum (DLSt), nucleus accumbens 
(NA), and lateral septal nucleus (LSN) and clozapine producing such effects in the NA, 
medial prefrontal cortex (mPFC), and LSN. More interestingly, maternal behavior itself also 
increases c-Fos expression in the NA and LSN, as well as in the medial preoptic area 
(MPOA) (Fleming et al., 1994b; Numan et al., 1998; Stack et al., 2002), Please ask au to 
confirm this deletionthe hypothalamic nucleus that is critical for the onset and maintenance 
of maternal behavior (Numan and Insel, 2003). Importantly, the intensity of c-Fos 
expression in MPOA maternal neurons has been found to be closely tied to the actual 
performance of the behavior (Numan and Numan, 1994; 1995).
In attempt to delineate the neural circuitry that mediates the maternal-disruptive effects of 
haloperidol and clozapine, we used the c-Fos immunohistochemistry technique together 
with the pharmacological tools and behavioral observations (Zhao and Li, 2010). The 
traditional approach in this field has been to examine brain regions that show drug-induced 
increase in c-Fos expression. Although it is straightforward, this approach has two problems. 
The first is that it fails to connect a drug’s behavioral effects with its neuronal effects. In a 
typical study, animals are injected with an antipsychotic drug in their home cages, and 
sacrificed 2 hours later for brain analysis. Animal behavior and behavioral effects of the 
drug treatment are generally ignored. This issue is further complicated by the fact that 
animal behavior itself can also induce brain changes as indexed by c-Fos expression. For 
example, maternal behavior can stimulate c-Fos expression in the MPOA, the ventral bed 
nucleus of the stria terminalis (vBST) and the NA (Fleming et al., 1994b; Numan and 
Numan, 1994; Lonstein et al., 1998). The second problem is that it does not take the 
neurochemical mechanisms of different antipsychotic drugs into consideration. As 
mentioned above, although both haloperidol and clozapine disrupt active maternal 
responses, they do so via blocking dopamine D2 and 5-HT2A/2C receptors, respectively. 
Thus, although both drugs can induce similar changes in c-Fos expression in the same brain 
regions, they may do so through distinct receptor mechanisms. Simply relying on the drug-
induced c-Fos expression does not guarantee a correct identification of receptor-mediated 
neuroanatomical basis of a drug action. With these considerations in mind, we divided 
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postpartum rats into nine groups using a full factorial design comprising 3 pretreatment 
conditions: saline, quinpirole or DOI × 3 antipsychotic conditions: sterile water, haloperidol 
or clozapine. On the drug test day (one day on either Postpartum Day 6, 7, or 8), all subjects 
were tested twice, with the first maternal behavior test starting at 30 min prior to the 
injections and the second test occurring at 120 min after injections. Quinpirole, DOI or 
vehicle was injected subcutaneously twice, with the first injection at 10 min before and the 
second at 50 min after the haloperidol, clozapine or vehicle injection, as was done in Zhao 
and Li (2009b). Two hours after drug administration, rats were sacrificed and their brains 
were removed and processed for FOS protein staining. The brain regions analyzed included 
the neural sites that were implicated in the action of antipsychotic drugs [e.g., mPFC, 
nucleus accumbence shell (NAs), nucleus accumbence core (NAc), DLSt, ventral part of 
lateral septal nucleus (LSv)], and/or in the regulation of maternal behavior [e.g., MPOA, 
vBST, medial amygdaloid nucleus (MeA) and NAs and NAc] (Li and Fleming, 2003a; b; 
Numan et al., 2005). We considered a brain region to be part of the neural circuitry of 
haloperidol or clozapine only if it mets the following three criteria: (1) it shows sensitive c-
Fos response to treatment with haloperidol or clozapine; (2) it shows sensitive c-Fos 
responses to the reversal effect of pretreatment with quinpirole on haloperidol or DOI on 
clozapine; and (3) it does shows little or no c-Fos response to the pretreatment with DOI on 
haloperidol or quinpirole on clozapine. This approach ensured that the brain regions 
identified are behaviorally and neurochemically relevant to the specific action of haloperidol 
and clozapine.
Behaviorally, we replicated our previous findings (Zhao and Li, 2009b). Both haloperidol 
and clozapine disrupted pup retrieval, pup licking and nest building, but not nursing. 
Pretreatment with quinpirole, but not DOI, reversed the haloperidol-induced disruptions; in 
contrast, pretreatment with DOI, but not quinpirole, reversed the clozapine-induced 
disruptions. Neuroanatomically, we found that seven brain regions showed a significant drug 
treatment effect on c-Fos expression. The only brain region that did not show any change 
was the MeA. In comparison to the vehicle treatment, haloperidol significantly increased c-
Fos expression in the NAs and NAc, DLSt and LSv, whereas clozapine significantly 
increased c-Fos expression in the NAs, LSv, vBST and mPFC. Quinpirole alone 
significantly increased c-Fos expression in the mPFC and vBST, while it decreased c-Fos 
expression in the NAs and NAc. DOI alone also significantly increased c-Fos expression in 
the mPFC, NAs, NAc, MPOA and vBST. Pretreatment with quinpirole significantly reduced 
the haloperidol-induced c-Fos increase in the NAs, NAc, DLSt and LSv, but also reduced 
the clozapine-induced c-Fos increase in the NAs. In contrast, pretreatment with DOI reduced 
the clozapine-induced c-Fos increase in the NAs, but did not alter the clozapine-induced c-
Fos increase in the mPFC, LSv and vBST. Pretreatment with DOI also significantly reduced 
the haloperidol-induced c-Fos increase in the NAs, NAc and DLSt.
Our further analysis which took the effects of quinpirole and DOI itself on c-Fos expression 
into consideration (e.g. quinpriole reduced, while DOI increased c-Fos expression in the 
NAs and NAc) indicates that pretreatment with quinpriole and DOI produced opposite 
patterns of c-Fos expression in the brain regions (e,g. NAs, NAc, LSv, or DLSt) where 
haloperidol and clozapine had an effect. These dissociated pretreatment patterns were 
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consistent with our findings that only pretreatment with quinpirole (but not DOI) can reverse 
the haloperidol-induced disruption, whereas only pretreatment of DOI (but not quinpirole) 
can reverse the clozapine-induced disruption (Zhao and Li, 2009a). Based on these results, 
we concluded that haloperidol disrupts active maternal behavior primarily by blocking 
dopamine D2 receptors in the neural circuitry involved the nucleus accumbens, lateral 
septum, and dorsolateral striatum. In contrast, clozapine disrupts active maternal behavior 
mainly by blocking serotonin 5-HT2A/2C receptors in the nucleus accumbens shell.
Olanzapine is a widely prescribed atypical antipsychotic drug with a high antagonist action 
against serotonin 5-HT2A/2C receptors, in addition to its action on D2 receptors (Bymaster et 
al., 1999a, b). Mechanistically, it shares the D2 antagonism with haloperidol and clozapine, 
and 5-HT2A/2C antagonism with clozapine. Thus, it resides in the pharmacological space in 
between (or combined with) haloperidol and clozapine in terms of D2 occupancy coupled 
with 5-HT2A/2C and other actions. Our previous work showed that both acute and chronic 
olanzapine treatments at a relatively high dose (7.5 mg/kg, sc) disrupt active components of 
maternal behavior (e.g., pup retrieval, pup licking and nest building) (Li et al., 2005a). 
However, little is known about the neural basis of the effect of olanzapine. In order to 
further delineate its neural basis we first established a dose-dependent function of the 
disruptive effect of olanzapine on rat maternal behavior (Zhao and Li, 2012). On postpartum 
Days 6–8, Sprague-Dawley mother rats were acutely injected with sterile water or 
olanzapine (1.0–5.0 mg/kg, sc). Maternal behavior was tested 2 h later, after which rats were 
sacrificed and brain tissues were collected and analyzed using c-Fos immunocytochemistry. 
We found that acute olanzapine treatment dose-dependently disrupted various components 
of maternal behavior (e.g., pup retrieval, pup licking, nest building, crouching) and 
increased c-Fos immunoreactivity in the mPFC, NAs and NAc, DLSt, LSv, CeA and VTA, 
important brain areas generally implicated in incentive motivation and reward processing. In 
contrast, olanzapine treatment did not alter c-Fos in the medial preoptic nucleus (MPN), 
vBST and medial amygdala (MeA), the core brain areas directly involved in the mediation 
of rat maternal behavior. These findings suggest that, like haloperidol and clozapine, 
olanzapine disrupts rat maternal behavior primarily by suppressing incentive motivation and 
reward processing via its action on the mesocortical and mesolimbic dopamine systems, but 
not by disrupting the core processes involved in the mediation of maternal behavior in 
particular.
The notion that antipsychotic drugs disrupt maternal behavior primarily by suppressing 
incentive motivation and reward processing, via their actions on the mesocortical and 
mesolimbic dopamine systems, is also consistent with other studies. For example, Keer and 
Stern (1999) showed that cis-flupenthixol (a mixed DA D1 and D2 receptor antagonist) 
microinfused into the nucleus accumbens (but not the dorsomedial striatum) disrupts pup 
retrieval and pup licking, but enhances nursing. In our study, we investigated the effects on 
maternal behavior of central infusion of haloperidol into the shell part of the nucleus 
accumbens (NA) (Li, 2002). We used a within-subjects design with each mother rat 
receiving two doses of haloperidol in a counterbalanced manner. We found that haloperidol 
at 5.0 μg/μl affected every component of maternal behavior. For example, it significantly 
impaired pup retrieval and nest building, but it increased pup nursing. This result was 
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consistent with the systemic haloperidol studies (Stern, 1991; Li et al., 2004), and further 
demonstrates that the NA shell may be one of the brain sites where haloperidol acts to 
disrupt maternal behavior.
In summary, recent work on the behavioral, neurochemical and neuroanatomical 
mechanisms of antipsychotic effects on maternal behavior in rats has suggested that 
antipsychotic drugs disrupt active maternal responses primarily by suppressing maternal 
motivation. The sedative effects of atypical drugs also contribute to their disruptive effect. In 
terms of receptor mechanisms, dopamine D2 receptors and serotonin 5-HT2A/2C receptors 
are both involved. D2 receptors contribute more to the haloperidol (maybe also other typical 
antipsychotics)-induced disruption of active maternal behavior and its enhancement of pup 
nursing, while 5-HT2A/2C receptors contribute more to the clozapine-induced disruption. 
Finally, using the c-Fos immunohistochemistry technique and microinjection, we 
demonstrated that the nucleus accumbens shell is an essential component of the neural 
system that supports the disruptive effect of antipsychotic drugs. Because much research in 
this area has been conducted in my laboratory, independent replication would greatly 
improve the validity of our conclusions.
Clinical implications and future research
As mentioned in the Introduction, studying antipsychotic drug effects on maternal behavior 
has important clinical implications for understanding the deficient maternal care provided by 
patients with schizophrenia. Clinical observations suggest that women with schizophrenia 
have sexual practices similar to those of demographically matched control subjects. Several 
studies have found that over half of the women with schizophrenia are also mothers, a rate 
that is comparable with the general population (Seeman, 2004). Like mothers with other 
mental illnesses, most mothers with schizophrenia raise their own children (Abel et al., 
2005), feel the pride of looking after a child, and many demonstrate a desire to take 
responsibility despite their mental illness and often adverse circumstances (Mowbray et al., 
1995). Studies on the mother-child relationship reveal that the quality of maternal care from 
schizophrenic mothers is generally inferior to that from healthy mothers (Bosanac et al., 
2003; Wan et al., 2008b). It has been reported that mothers with schizophrenia show fewer 
positive emotional responses and less social contact with their infants than do healthy 
mothers (Persson-Blennow et al., 1984; McNeil et al., 1985; Naslund et al., 1985; Persson-
Blennow et al., 1986). They are generally more remote, silent, insensitive, and unresponsive 
during mother-infant play, and they are less demanding of their infants (Riordan et al., 1999; 
Snellen et al., 1999). Their interaction with infants is less mutually satisfying, less excited, 
and more serious (Riordan et al., 1999). Mothers with schizophrenia as a group show more 
non-responses and more abnormal behaviors as a result of being psychologically withdrawn 
from the interaction (Wan et al., 2008b). These suboptimal patterns of maternal responding 
in mothers with schizophrenia are found to be dissociable from infant inertness, negativity 
or low initiation (Wan et al., 2008b), although some reports show that infants of mothers 
with schizophrenia are more avoidant than normal infants (Riordan et al., 1999).
A number of contributing factors to this impaired relationship have been identified, 
including positive and negative symptoms, cognitive deficits, social cognitive impairments, 
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social stress such as stigma, and a lack of protective factors (Wan et al., 2007). For example, 
the mother may be inattentive to the needs of her baby because her delusions or 
hallucinations demand preferential attention. She may also be unavailable to her baby due to 
a lack of motivation to care for her baby (Snellen et al., 1999). Her attention deficits may 
severely hamper her interaction skills, such as timely responding to the infant’s signals. Her 
cognitive deficits may affect her ability to provide the appropriate support for her child’s 
cognitive development (Wan et al., 2008a). Therefore, antipsychotic drugs could 
conceivably improve maternal care in schizophrenic mothers by controlling various 
symptoms of schizophrenia (especially the positive symptoms) (Seeman, 2004), given their 
known clinical efficacy against positive and negative symptoms of schizophrenia and 
cognitive impairments (Meltzer, 2013).
On the other hand, antipsychotic medications could also interfere with parenting – mother 
patients are aware of the problems of taking antipsychotic drugs but fear the alternatives. 
Some mothers reported purposely missing their medications in order to stay alert and 
focused on their child (Seeman, 2004). Mechanistically, it is well known that antipsychotics 
can give rise to the “neuroleptic-induced deficit syndrome” (NIDS) (Awad, 1993; Awad and 
Hogan, 1994), a state in which there is poverty of speech, flattened affect, loss of drive, and 
social withdrawal. Since NIDS’s clinical presentations are similar to the negative symptoms 
of schizophrenia, antipsychotics could conceivably disrupt maternal behavior through 
similar mechanisms. The preclinical work summarized in this review provides a strong 
support for this notion, although we need to be careful in assuming that similar behavioral 
effects would be observed in both normal and “diseased” animals. For human research, as 
both antipsychotic drugs and schizophrenic symptoms jointly affect maternal care, the key 
issue is to identify the possible interactive effects of schizophrenic symptoms and 
antipsychotic medications on the quality of maternal care.
Overall, research in this area not only enhances our understanding of how antipsychotic 
medications impact the quality of maternal care, but also helps in identifying the relevant 
psychological and neurobiological mechanisms responsible for antipsychotic action, as well 
as understanding the neurobiology of maternal behavior. This work will certainly help us 
develop better psychological and pharmacological intervention strategies to improve 
maternal care in patients with schizophrenia. For example, if results from this project 
support our hypothesis that antipsychotics reduce the quality of maternal care by decreasing 
motivation to care for the young, behavioral interventions based on increasing mothers’ 
motivation to care for the young may have a better chance of being successful. Furthermore, 
if blocking dopamine D2 and 5-HT2A/2C receptors turns out to be the main cause of impaired 
maternal care, pharmacological interventions based on enhancing dopamine D2- and 5-
HT2A/2C-mediated transmission may be a valid approach.
One future research will further delineate the neuroreceptor mechanisms of antipsychotic 
effects on maternal behavior. Because none of the tested antipsychotics targets only one 
receptor system, and quinpirole and DOI have actions on at least two different receptors (D2 
and D3 for quinpirole and 5-HT2A and 5-HT2C for DOI), the exact receptor that mediates the 
maternal-disruptive effect of haloperidol, clozapine and olanzapine is uncertain. It will be 
important to use more selective agonists or antagonists to help delineate the receptor 
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mechanisms of antipsychotic action. For example, we may be able to use the selective 5-
HT2A receptor antagonist M100907 and the selective 5-HT2C receptor antagonist SB242084 
together with DOI to specify the relative importance of 5-HT2A and 5-HT2C receptors in the 
mediation of the maternal disruptive effect of atypical antipsychotics. Another future project 
will use highly selective receptor antagonists for D2, D3, 5-HT2A, or 5-HT2C receptor to 
simulate the effects of antipsychotic drugs. For example, we could treat postpartum female 
rats with either a selective D2 antagonist raclopride, the 5-HT2A antagonist M100907, or 
both raclopride and M100907 to see which condition produces a close simulation of the 
effect of an atypical antipsychotic such as clozapine and olanzapine. Furthermore, we could 
use double staining techniques to identify the specific types of neurons (dopaminergic, 
serotoninergic or GABAergic) that show an increase in c-Fos expression in response to the 
antipsychotic treatment.
To further examine the neuroanatomical basis of antipsychotic effects, it will be important to 
use the information garnered from the c-Fos study and examine whether atypicals such as 
risperidone, quetiapine and aripiprazole also act through the nucleus accumbens shell-related 
reward neural circuitry to disrupt maternal behavior. Similarly, one could microinject 
antipsychotic drugs or various dopamine or serotonin agonists or antagonists in various 
brain regions to examine their possible interactions with antipsychotics. Future work 
employing this microinjection technique will be necessary to verify the neural systems for 
each drug. All these behavioral, neuroreceptor and neuroanatomical levels of research 
should also be conducted in animal models of postpartum psychosis (and depression and 
anxiety) to enhance their clinical relevance. The use of normal rats is good for isolating the 
impact of antipsychotic treatment from that of schizophrenia symptoms, but this approach 
could not delineate the intricate interactions between these two sources of impact on 
maternal care. In this regard, development and validation of animal models of postpartum 
psychosis is urgently needed.
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